GlassScriptPhysician profile
Gildardo Ceballos
NPI 1689956906
$5,322.26
in general payments reported to CMS, 2019-2025
42 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $120 · 2021: $124 · 2022: $250 · 2023: $825 · 2024: $1,116 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $716.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $710.74 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $538.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $358.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $337.52 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $297.60 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $263.03 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $235.99 | 2024-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.44 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $191.08 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $146.85 | 2019-2024 | Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $133.81 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.69 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $120.19 | 2020 | |
| Allergan, INC. | $83.13 | 2019 |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gildardo Ceballos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.